Nymox Pharmaceutical Corp
NYMX
NYMX was delisted on the 6th of July, 2023.
38 hedge funds and large institutions have $3.8M invested in Nymox Pharmaceutical Corp in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 13 reducing their positions, and 8 closing their positions.
13% more call options, than puts
Call options by funds: $69K | Put options by funds: $61K
2.01% less ownership
Funds ownership: 5.06% → 3.06% (-2%)
7% less funds holding
Funds holding: 41 → 38 (-3)
23% less capital invested
Capital invested by funds: $4.97M → $3.8M (-$1.17M)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
69% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
WMS Partners
Towson,
Maryland
|
+$31.5K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$24.3K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$22.7K |
| 4 |
Renaissance Technologies
New York
|
+$7.85K |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$1.75K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.22M |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$381K |
| 3 |
Goldman Sachs
New York
|
-$220K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$147K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
-$102K |
NYMX Hedge Fund Activity: Q3 2019 in Review
38 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q3 2019, worth a combined $3.8M — down 23% from $4.97M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of NYMX and 5 opened new positions — a net loss of 3 holders — while 13 trimmed existing stakes and 4 added.
The largest buyer was WMS Partners, opening a new position worth an estimated $31.5K. The largest seller was Millennium Management, cutting an estimated $1.22M.
- 38 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q3 2019, down from 41 in Q2 2019.
- Funds reported $3.8M of Nymox Pharmaceutical Corp stock for Q3 2019, down 23% quarter-over-quarter.
- 5 funds opened new Nymox Pharmaceutical Corp positions in Q3 2019 and 8 closed out, a net change of -3 holders.
- The largest Nymox Pharmaceutical Corp buyer in Q3 2019 was WMS Partners, an estimated $31.5K added.
- The largest Nymox Pharmaceutical Corp seller in Q3 2019 was Millennium Management, an estimated $1.22M sold.
Based on aggregated 13F filings for Q3 2019.